


**ANNUAL
REPORT**


2016



THE INNOVATION FUND

CONTENT

04	The investors	18	INVESTMENTS ON APRIL 30 TH , 2017
06	Report from the Board	20	InOpSys
08	Accounts 2016	22	Lisam
10	Report of the auditor	24	PharmaFluidics
14	Governance	26	Trendminer
		28	X4C
		30	Fyteko
		32	Mathym
		34	Aerosint



THE INNOVATION FUND

The Innovation Fund was created in 2015 at the instigation of Innovation Circle, an association of 13 individuals dedicated to the support of innovation in the Chemistry and Life Sciences industries.

Its initial capital of 13,4 Mo€ was raised to 20 Mo€ in 2016.

The fund's mission is to finance start-ups in the Chemistry and Life Sciences and to promote progress and employment in Belgium and in surrounding regions.

THE INVESTORS

—
INVESTORS, MEMBERS OF THE BOARD
AND OF THE INVESTMENT COMMITTEE
—



—
INVESTORS, MEMBERS OF THE BOARD
—



UNIQUE
THANKS
TO THE
IMPLICATION
OF ITS
INVESTORS

Dear shareholders,

Since its inception two year ago, Innovation Fund has confirmed the relevance of its mission by financing motivated entrepreneurs, innovative projects, new processes and new products.

InOpSys is a provider of unique solutions for the treatment of the process water of the pharmaceutical and chemical industries.

Lisam is distributing worldwide its software for the regulatory filings of the chemical industry.

Pharmafluidics designs high performance chromatography columns derived from chip making technology.

X4C has developed a unique surface treatment and functionalising technology.

Trendminer produces datamining software to detect patterns leading to failures or breakdowns in the process industry.

Fyteko is testing new bio-stimulants, with reproducible attributes, for the agriculture and horticulture.

Mathym synthesises colloidal nanoparticles as building blocs for the dental industry.

One investment occurred after year end 2016.

Aerosint is conceiving a new 3D printing head for selective laser sintering.

Several of these companies will start selling their first products during 2017.

The Fund had naturally no proceeds in 2016 and the accounts of the year show a loss of 413.818€, essentially constituted by the management fee of Eebic Ventures.

Accounting rules on discontinuity are not applicable. The total balance sheet amounts to 9.321.565€ and the board will recommend to the general assembly the report of the accumulated loss to the next accounting year. The first exits are not expected before 2020, hence the most likely result for 2017 will be a loss equivalent to the management fees.

The Board did call for the release of a second tranche of the unpaid capital, for an amount of 5Mo€, payment happened partly in 2016 and the balance was paid in 2017.

At this date, the Fund has invested close to 4 Mo€, committing close to 8Mo€, reaching its mid-life ahead of time. We consider, accordingly, transforming the closed fund into an evergreen fund.

We hope that Innovation Fund offers its shareholders a view on innovation, a platform for exchanges and a profitable venture. We thank them for their support and active participation in our studies and evaluations.

The Board thanks management for their efficiency in identifying new projects and for their dedication to the success of the fund.

We hope that 2017 will see our first start ups succeed and will bring new projects.

For the board of directors,



—
François Cornelis
Chairman

ANNUAL ACCOUNTS

ASSETS

		2016	2015
fixed assets	20/28	2.937.104	534.405
formation expenses	20	41.961	43.394
formation & capital increase expenses		66.012	
amortization on formation expenses		-24.051	
financial assets	28	2.895.143	500.011
investment InOpSys		500.011	500.011
investment Lisam Systems		250.000	
investment PharmaFluidics		364.992	
investment TrendMiner		1.000.002	
investment X4C		30.000	
investment Fytekko		500.000	
investment Fytekko (uncalled)		-250.000	
investment Mathym		500.139	
current assets	29/58	6.384.462	3.643.966
amounts receivable within one year	40/41	1.062.511	1.210
unpaid capital		1.062.500	
taxes to be recovered		10,10	
cash at bank and in hand	54/58	5.321.924	3.642.756
accrued Income	490/1	28	
total assets		9.321.565	4.178.371

LIABILITIES

		2016	2015
capital and reserves	10/15	9.316.641	4.130.459
capital	10	10.000.000	4.400.000
issued capital	100	20.000.000	17.300.000
uncalled capital	101	-10.000.000	-12.900.000
loss carried forward	141	-683.360	-269.541
amounts payable	17/49	4.925	56.895
suppliers	44	4.719	56.894
accrued charges	492/3	206	18
total liabilities		9.321.565	4.187.371

INCOME STATEMENT

		2016	2015
operating income & charges	60/61		
operating charges	61	-400.074	-258.185
management fees		-390.777	-251.500
accounting fees		-4.524	-1.736
auditor's fees		-4.774	-4.949
depreciation of formation expenses	630	-13.203	-10.850
other operating charges	640/8	-348	-447
social contribution of the company		-348	-447
operating loss	64/70	-413.624	-269.481
financial income	75	65	
financial charges	65	-259	-60
loss for the period to be appropriated	68/70	-413.818	-269.541

APPROPRIATIONS & TRANSFERS

		2016	2015
loss to be appropriated	69/70	-683.359	-269.541
loss for the period available for appropriation	68/70	-413.818	
loss brought forward	690	-269.541	
loss to be carried forward		-683.359	-269.541

STATUTORY AUDITOR'S REPORT TO THE GENERAL ASSEMBLY OF SHAREHOLDERS ON THE FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31ST, 2016

Ladies and Gentlemen,

As required by law and the company's by-laws, we report to you in the context of our statutory auditor's mandate. This report includes our opinion on balance sheet as at December 31st 2016, the income statement for the year then ended, and the disclosures, as well as the required additional statements.

REPORT ON THE ANNUAL ACCOUNTS UNQUALIFIED OPINION

We have audited the annual accounts of the company INNOVATION FUND for the year 2016 ended 31st december 2016, prepared in accordance with the financial-reporting framework applicable in Belgium, which show a balance sheet total of € 9.321.564,85 and a loss for the year of € 413.818,24

RESPONSIBILITY OF THE BOARD OF DIRECTORS FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The board of Directors is responsible for the preparation of annual accounts that give a true and fair view in accordance with the financial-reporting framework applicable in Belgium, and for such internal control as the board of Directors determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

RESPONSIBILITY OF THE STATUTORY AUDITOR

Our responsibility is to express an opinion on these annual accounts based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISAs).as adopted in Belgium Those standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the annual accounts are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the annual accounts. The procedures selected depend on the statutory auditor's judgment, including the assessment of the risks of material misstatement of the annual accounts, whether due to fraud or error. In making those risk assessments, the statutory auditor considers the company's internal control relevant to the preparation of annual accounts that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the board of Directors, as well as evaluating the overall presentation of the annual accounts..

We have obtained from the board of Directors and company officials the explanations and information necessary for performing our audit.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

UNQUALIFIED OPINION

The board of Directors is responsible for the preparation and the content of the Director's report, as well as for the compliance with the legal and regulatory requirements regarding bookkeeping, with the Company Code and with the company's by-laws.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

The board of Directors is responsible for the preparation and the content of the Director's report, as well as for the compliance with the legal and regulatory requirements regarding bookkeeping, with the Company Code and with the company's by-laws.

In the context of our mandate and in accordance with the Belgian standard which is complementary to the International Standards on Auditing (ISAs) as applicable in Belgium, our responsibility is to verify, in all material respects, compliance with certain legal and regulatory requirements. On this basis, we make the following additional statements, which do not modify the scope of our opinion on the annual accounts:

- The Director's report prepared in accordance with the articles 95 and 96 of the Company Code and to be deposited in accordance with article 100 of the Company Code, includes, both in terms of form and content, the information required by the law, is consistent with the annual accounts and does not present any material inconsistencies with the information that we became aware of during the performance of our mandate.
- The list of the enterprises in which the enterprise holds a participating interest, to be deposited in accordance with article 100 of the Company Code, includes, both in terms of form and content, the information in accordance with the legal requirements and does not present any material inconsistencies with the information we have at our disposal in our audit file.
- Without prejudice to certain formal aspects of minor importance, the accounting records are maintained in accordance with the legal and regulatory requirements applicable in Belgium.
- The appropriation of results proposed to the general meeting complies with the relevant requirements of the law and the company's by-laws.
- There are no transactions undertaken or decisions taken in breach of the by-laws or of the Company Code that we have to report to you.

Brussels, April, 21st 2017

B S T

BST Réviseurs d'Entreprises,
S.C.P.R.L. de réviseurs d'entreprises,
represented by Pascale TYTGAT,
Statutory Auditor

THE GOVERNANCE

THE BOARD



From left to right: Mr. Philip BUSKENS, Mr. Karl ADAMS, Mr. Thierry PIRET, Mrs. Nathalie BRUNELLE, Mrs. Anne PRIGNON, Mr. Olivier CHAPELLE, Baron François CORNELIS (Chairman), Mr. Luc REGINSTER, Mrs. Sylvie CRETEUR, Mr. Jean-Marie SOLVAY, Baron Rodolphe COLLINET, Mr. François FONTAINE & Mr. Jos BEHIELS

Baron François CORNELIS, Chairman

Mr. Christian COLLETTE, Vice President R&D, ARKEMA

Mr. Koenraad DEBACKERE, General Manager, KULEUVEN

Mr. Paul DEPUYDT, CFO, RAVAGO

Mr. Luc REGINSTER, President, OFFICIUM

Mr. Jean-Marie SOLVAY, Board member, SOLVAY

BASF ANTWERPEN, represented by Mr. Philippe BUSKENS

CARMEUSE represented by Baron Rodolphe COLLINET

IMBC SPINNOVA represented by Mrs. Sylvie CRETEUR

ING BELGIQUE represented by Mr. Jos BEHIELS

MEUSINVEST represented by Mr. Gaëtan SERVAIS

RECTICEL represented by Mr. Olivier CHAPELLE

SAMBRINVEST SPIN-OFF/SPIN-OUT represented by Mrs. Anne PRIGNON

S.F.P.I. represented by Mr. François FONTAINE

SIOEN INDUSTRIES represented by Mr. Joost WILLE

SOFIPÔLE (SRIW) represented by Mr. Karl ADAMS

SOLVAY represented by Mr. Thierry PIRET

SOUDAL Holding represented by Mr. Jurgen VANDERVELDE

TOTAL PETROCHEMICALS & REFINING represented by Mrs. Nathalie BRUNELLE

**THE
INVESTMENT
COMMITTEE**



From left to right: Mr François FONTAINE, Mr. Carl VAN CAMP, Mr. Serge DEMOULIN, Mrs Aude THIBAUT DE MAISIÈRES, Mr. Xavier DAIVE, Baron François CORNELIS (Chairman), Mr. Luc REGINSTER, Mr. Michiel ALLAERTS, Mr. Christian JOURQUIN, Mr. Thierry PIRET & Mr. Yves Meurice

Baron François CORNELIS, Chairman

Mr. Michiel ALLAERTS, Financials & Operations, RAVAGO

Mr. Edouard CROUFER, INNOVATION CIRCLE*

Mr. Vincent DABAS, Head of Prospective & New Technologies, TOTAL RC*

Mr. Xavier DAIVE, Investment Manager, SAMBRINVEST

Mr. Serge DEMOULIN, Senior financial analyst, IMBC

Mr. François FONTAINE, Investment Manager, SFPI

Mr. Christian JOURQUIN, INNOVATION CIRCLE**

Mr Olivier GREINER, Vice President Research & Development, TOTAL RC**

Mr. Fabian MARCQ, Deputy General Manager, MEUSINVEST

Mr. Yves MEURICE, Investment Manager, SRIW

Mr. Thierry PIRET, Head of Solvay Ventures, SOLVAY

Mr. Luc REGINSTER, President, OFFICIUM

Mrs. Aude THIBAUT DE MAISIÈRES, Board Member, SOLVAC

Mr. Carl VAN CAMP, INNOVATION CIRCLE**


Mr. Paul VAN DUN, Head of Leuven Research & Development (LRD), KULEUVEN

Baron Luc VANSTEENKISTE, INNOVATION CIRCLE*

(* Until December 31, 2016

(**) Since January 1, 2017

INVESTMENTS ON APRIL 30TH, 2017



InOpSys



COMPANY DESCRIPTION

Sector: Recycling Technology
Activity: Flexible & mobile units for wastewater treatment
Founders: AvOre (Steven De Laet, Luc Varigas, Erik Kiekens), Raf De Wil & Lise Appels
Registered Office: 12A Zandvoortstraat, 2800 Mechelen
Board Member representing IF in InOpSys: Pol-Henry Bonte

InOpSys provides an innovative and sustainable on-site solution for the treatment of process water of chemical and pharmaceutical industries. InOpSys delivers flexible, mobile and modular units, tailor-made for the treatment of waste water, eliminating the need for transport and incineration. The recuperation of valuable components is realized whenever feasible hence aiming to implement circular economy.

The company, created in 2015, combines in-house expertise originating at KU Leuven or AvoRe and validated proof of concept on a dozen aqueous waste streams at one of the world's largest manufacturer of pharmaceutical products. The project grew in FiSch (now Catalisti) and was further supported by the Innovation Circle during 2 years.

DEAL BACKGROUND & INVESTMENT RATIONALE

The knowhow developed at KU Leuven in advanced oxidation process is unique. As is the idea of using mobile modular units. The proof of concept was reached; investment was needed for the scale up.



Steven De Laet
Managing Director

"The investment by Innovation Fund made it possible for InOpSys to develop and implement an innovative and sustainable solution for the chemical and pharmaceutical industry. This solution will change the wastewater treatment industry."



FTE's end of 2016	4
increase in FTE's 2016/2015	2
sales 2016	55.881 €
increase in sales 2016/2015	55.881 €
EBITDA 2016	-288.000 €

TRANSACTION SUMMARY

On December 18th, 2015, the Innovation Fund and Gemma Frisius invested EUR 500.000 each in InOpSys. An additional investment is planned for 2017 depending on the completion of certain intermediate steps.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
Avore	35,48
Raf Dewil	12,39
Lise Appels	6,19
KULeuven	13,68
INNOVATION FUND	16,13
Gemma Frisius	16,13
total	100,00

KEY EVENTS AND ACTIONS IN 2016

In 2016 the management team was put in place. The construction of the first unit started. A first commercial contract with a major pharmaceutical company was signed, that initiated the construction of the second unit. The team is strengthened with a Project Manager/On-site engineer and a QESH manager.

EXPECTATIONS 2017

A second contract is expected to be signed upon successful delivery of the first treatment unit. The management targets 4 contracted units by year end 2017. Other targets for 2017 are the obtaining of ISO9001:2015 and SCC certifications.

SALES FORECAST in 000 EUR





COMPANY DESCRIPTION

Sector: Software

Activity: Management services for legal documents & reports on the environment, health & safety for different industrial sectors including chemistry

Founders: Michel Hemberg & Thierry Levintoff

Registered Office: 42A Boulevard de la Sennette, 7190 Ecaussinnes

Board Member representing IF in Lisam: François Cornelis

Founded in 1999, Lisam Systems is a software company focusing on developing Health, Safety and Environment packages to allow chemical industries to comply with their regulatory obligations.

The main focus of Lisam is to develop software to automate the authoring of Safety Data Sheet (SDS) compliant with the new UN regulation called Global Harmonized System (GHS).

The SDS authoring automation solution is the stepping stone for Lisam to add new modules such as regulatory data management, regulatory supply chain management and risk assessment to its offering.

DEAL BACKGROUND & INVESTMENT RATIONALE

Lisam is an established software company growing steadily from year to year and focused on some of the regulatory aspects of the chemical industry. Lisam benefits from access to the innovation Fund's industry network.

"The first 250k investment done by Innovation Fund in Lisam Systems is mainly to reinforce Lisam's capacity to handle larger M&A projects in the future. It helps us to formalize our financial objective and our reporting and it gives us access to a business network inside the chemical industry. With a yearly subscription fee moving from 5.5 to 6.5 million EUR, we delivered a company value growth close to 20%. We are convinced that we can maintain a similar growth rate in the coming years allowing Innovation Fund to exit with the expected return."



Michel Hemberg
Managing
Director



FTE's end of 2016	120
increase in FTE's 2016/2015	16
sales 2016	12 Mo €
software subscription fees 2016	6,5 Mo €
increase in software subscription fees 2016/2015	1 Mo €
EBITDA 2016	1,1 Mo €
increase in EBITDA 2016/2015	0,1 Mo €

TRANSACTION SUMMARY

On January 28th, 2016, the Innovation Fund invested EUR 250.000 in LISAM.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
Lisam H.Q.	99,26
INNOVATION FUND	0,74
total	100


KEY EVENTS AND ACTIONS IN 2016

In 2016, the main business objectives of the company were to extend the regional support of its SDS authoring software to new regions (like China, Brazil, Turkey, Korea) and to improve the quality of the regulatory support of its software for the 14 already existing regions.

EXPECTATIONS 2017

With the hiring of 40 new colleagues, Lisam intends to improve the quality of its global GHS coverage by expanding into new regions: South Africa, Italy, Argentina, Russia and Taiwan. The R&D team is working on new modules for regulatory data management and supply chain workflow.

SALES FORECAST IN YEARLY SUBSCRIPTION FEES (MAIN KPI) in 000 EUR



Pharma Fluidics



COMPANY DESCRIPTION

Sector: Process Technology

Activity: New generation of micro-Chip based analytical HPLC (liquid chromatography) columns

Founders: Paul Jacobs, Wim De Malssche, Gert Desmet & Joeri Denayer

Registered Office: Technologiepark, 3 Zwijnaarde, 9052 Zwijnaarde

Board Member representing IF in PharmaFluidics: Marie Bouillez

Created in 2010, PharmaFluidics is a spin-off of the Vrije Universiteit Brussels, located in Flanders' "Life Sciences valley", near Ghent, Belgium. The key expertise of PharmaFluidics is the design, lithographic production and surface treatment of silicon wafers for use as separation devices in chromatography. PharmaFluidics has developed a series of game-changing analytical HPLC products. With their unprecedented resolution performance, PharmaFluidics' μ PAC[®] micro-Chip based chromatography columns detect more molecules, with higher sensitivity, in tiny, complex biological samples. The μ PAC[®] micro-Chip based chromatography columns are commercially available for proteomic and metabolomic profiling.

DEAL BACKGROUND & INVESTMENT RATIONALE

PharmaFluidics has been able to define specifications for a first generation of innovative commercial chromatography columns. The proceeds of the capital increase will be used for the market launch and commercial validation of these products in selected high value niche markets. Part of the proceeds will also be used to develop new application fields and reference cases, and hence to broaden the market beyond the current pioneer users.

"Due to their unprecedented resolution performance, there is a bright future for μ PAC[®] micro-Chip columns: the impact of the μ PAC[®] micro-Chip columns on the global 1,5 BUSD HPLC columns market will be quick initially and will offer very substantial industry renewal and innovation for this industry in the medium to long term."



Johan Devenyns,
Managing
Director



FTE's end of 2016	6
increase in FTE's 2016/2015	2
sales 2016	152.000 €
increase in sales 2016/2015	+350%
EBITDA 2016	-716.000 €
increase in EBITDA 2016/2015	-583.000 €

TRANSACTION SUMMARY

In May 2016, Innovation Fund invested 200.000 EUR in PharmaFluidics. At year end 2016 existing investors and management syndicated a capital increase totalling 1,6 Million Euro. IF invested a further 165.000 EUR. The company will use it to achieve commercial validation of its first generation of μ PAC[®] products.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
founders & management	6,98
VUB	1,56
PMV	15,88
PMV - VI Gewest	19,73
Qbic	35,61
Theodorus	10,12
INNOVATION FUND	10,12
total	100,00


KEY EVENTS AND ACTIONS IN 2016

Johan Devenyns joined as CEO in August. PharmaFluidics moved to new premises. The company extended its Key Opinion Leaders network and number of applications, more particularly in proteomics and metabolomics profiling applications. Further work was performed on updating its corporate identity, visibility/website and coining a trade-mark μ PAC[®]. PharmaFluidics also defined the specifications for a range of commercial μ PAC[®] micro-Chip chromatography products ready for launch.

EXPECTATIONS 2017

PharmaFluidics' main objectives for 2017 are centred on the market launch and commercial validation of its first generation of μ PAC[®] micro-Chip chromatography columns in selected high value niche markets: metabolomics and proteomics profiling applications. A comprehensive awareness and technical support program is currently deployed to develop an additional range of novel applications. Furthermore, engineering and design work continues to improve product performance.

SALES EVOLUTION in 000 EUR



Trendminer



COMPANY DESCRIPTION

Sector: Software

Activity: Search, diagnostics, predictive analysis

Founders: Bert Baeck, Thomas Dhollander, Nick Vandamme, Niels Verheijen & Bart de Moor

Registered Office: Kempische Steenweg 297, 3500 Hasselt

Trendminer was founded in January 2008 as a spin-off of the University of Leuven. The first sales were realised in 2014.

TrendMiner's mission is to "Help Global Manufacturing Companies Improve their Plant Availability and Overall Asset Effectiveness Through Search, Diagnostic and Predictive Analytics using Pattern Recognition and Machine Learning Technology."

TrendMiner operates in a highly competitive market that is dominated by large conglomerates. TrendMiner has developed a different approach, centered on Joint Innovation. Being a young and agile team, they are closer to the customer than any other company.

Trendminer has its global headquarters in Hasselt and sales office and regional headquarters in Houston, Texas, in the heart of the biggest chemical and oil & gas market of the US.

DEAL BACKGROUND & INVESTMENT RATIONALE

TrendMiner has developed a powerful tool based on pattern recognition to improve plant data analysis. It had just moved out of beta and was keen to develop its commercial reach through the network of Innovation Fund.



Bert Baeck
Managing
Director

"In case of the Innovation Fund, the network effect really works. I am happy to have the IF as a strategic partner and shareholder on board."



FTE's end of 2016	33
increase in FTE's 2016/2015	17
monthly recurring revenues YE 2016	210.000 €
increase monthly recurring revenues 2016/2015	79.000 €

TRANSACTION SUMMARY

The initial capital of 135 kEUR was increased in 2 rounds: 2,5 Mo EUR in 2010 from LRM, PMV and Gemma Frisius and 5 Mo EUR in 2015, where Fortino and Jurgen Ingels joined the other investors. In June 2016, Innovation Fund invested EUR 1 Mo in TrendMiner to increase its runway and accelerate its commercial roll out.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
founders	5,26
KU Leuven	2,31
LRM	36,79
PMV (& Flemish Region)	12,92
Fortino	21,38
JInvest	1,96
Gemma Frisius	11,22
INNOVATION FUND	8,16
total	100

KEY EVENTS AND ACTIONS IN 2016

TrendMiner achieved a number of milestones in 2016. The monthly recurring revenue increased by 240% while Research & Development was scaled up to 33 FTE's in order to further improve the product offering. Trendminer won an extremely important contract with TOTAL Refining and Chemicals for a global roll-out. The introduction at high level in the company thanks to Innovation Fund and the quality of

the delivered services proved a successful combination.

EXPECTATIONS 2017

TrendMiner intends to develop additional modules: asset analytics capabilities and hypothesis generation. Monthly recurring revenue is expected to double. To accelerate the development of the company, a new stock offering will be proposed. Payroll should increase to 55 FTE.

SALES EVOLUTION in 000 EUR



X4C



COMPANY DESCRIPTION

Sector: Materials

Activity: Single layer in calix (4) arene for post-functionalisation

Founders: Alice Mattiuzzi

Registered Office: Rue Chêne Bonnet, 128
6110 Montigny-le-Tilleul

Board Member representing IF in X4C: Pol-Henry Bonte

X4C is a recently created spin-off company from Brussels University (2016). X4C has developed an innovative surface coating solution for high-end applications. X4C's core technology is based on the covalent grafting of calix[4]tetra-diazoniums groups. Their cyclic structure allows adding new, attractive properties to the more conventional aryl-diazonium groups.

X4C can develop, on any surface, a well-organized, well-controlled, compact and robust monolayer, that can be easily post-functionalised in a well-organised way.

This combination of otherwise antinomic properties pushes the boundaries of what can be applied on any substrate and opens doors to exciting new applications in different sectors such as optic, electronic, medical devices, diagnostic and many others.

DEAL BACKGROUND & INVESTMENT RATIONALE

Different sources confirmed the real interest of X4C technology. Although considered as too early stage for the fund, we decided to give the new start up seed money in order to initiate the commercial contacts.

"IF's commitment to the creation of X4C boosted the credibility of the project and provided a network of potential prospects; it was an important first signal that a new, innovative solution could become a worldwide new standard in the coating industry."



Mattiuzzi Alice
Managing
Director



investment	30.000 €
FTE's end of 2016	1

TRANSACTION SUMMARY

On July 15th, 2016, Innovation Fund invested 30.000 € in X4C, in a co-investment with Sambrinvest (30.000 €) and Theodorus (45.000 €). If the commercial contacts prove successful a follow on investment will be done in 2017.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
founders (A.Mattiuzzi)	13,00
Mr Pagnouille	7,00
Sambrinvest	23,00
Theodorus	34,00
INNOVATION FUND	23,00
total	100,00

KEY EVENTS AND ACTIONS IN 2016

X4C was created in July 2016, with Alice Mattiuzzi as a founder and CEO. Several commercial contacts have been made and first feasibility studies are underway in Optical, Medical Devices and Electronics.

EXPECTATIONS 2017

X4C will carry out optimisation studies in Optical and Medical Devices. The company needs to find its first clients in order to insure its future.

SALES FORECAST in 000 EUR



Fyteko



COMPANY DESCRIPTION

Sector: Biosciences

Activity: Organic biostimulants to boost plant resistance

Founders: Guillaume Wegria & Juan Carlos Cabrera

Registered Office: Clos Capelle-aux-Champs 30, 1200 Bruxelles

Board Member representing IF in Fyteko: Caroline Limbosch

Fyteko was created in 2014 by Guillaume Wegria and Dr Juan Carlos Cabrera. Fyteko develops new innovative & sustainable solutions for agriculture through biocatalysis. Fyteko created and patented a family of macromolecules to be used in agriculture. One of these macromolecules induces and strengthens the plant's natural metabolism by boosting specifically proline metabolism (acting on osmoregulation in plants). This product enables crops to better tolerate droughts and recover better and faster after a rainfall. Different formulations are currently being field tested by distributors in different parts of the world. Fyteko's DNA lies in innovation, the R&D team is therefore already starting to work in the upcoming innovation and application of the products whilst the sales team concentrates on the sales contacts and the homologation of this first products (NURSPRAY and NURSEED).

DEAL BACKGROUND & INVESTMENT RATIONALE

Innovation Fund invested in Fyteko based on the promising results from laboratory and greenhouse tests. The fund was also able to contribute additional marketing and distribution expertise and expects that one of its shareholders will sign a cooperation agreement with Fyteko in the course of 2017.

Guillaume Wegria
General
Manager



"Innovation Fund's investment into our start-up enables us to grow faster and structure ourselves in a more secure way. To us, the choice of Innovation Fund was not done on financial issues but for their ability to provide us with contacts and advices from key leaders of our sector. This, combined with shared vision and values will bring fyteko to its best! For us, the key of a successful partnership."



FTE's end of 2016	3,5 FTE
increase in FTE's 2016/2015	+1
sales 2016	7.000 €
sales 2015	0 €

TRANSACTION SUMMARY

On September 29th 2016, the Innovation Fund invested EUR 250,000 in Fyteko, and took the commitment to invest another EUR 250.000 based on a field test milestone.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
Guillaume Wegria	42,78
Juan Carlos Cabrera	35,00
INNOVATION FUND	22,22
total	100

KEY EVENTS AND ACTIONS IN 2016

2016 was for Fyteko the start of commercial contacts, cooperation's agreements and field tests in Argentina and Chili while further improving the formulations. Application was made for a European R&D subsidy. A first recruitment outside of the founder's team was made. Fyteko was recognised by an MIT Innovators under 35 award and selected as one of the top 50 Belgian start-ups to invest in.

EXPECTATIONS 2017

Fyteko expects the first batches of results of field test in areas suffering from abiotic stress and will sign additional distributors. This should lead to negotiations and potential test sales in 2018. Fyteko will start the Belgian homologation of its foliar spray (NURSPRAY). This will help registration in other countries and increase the credibility of the product. R&D remains the top priority of the company.

SALES FORECAST in 000 EUR



Mathym



COMPANY DESCRIPTION

Sector: Materials science

Activity: Synthesis of colloidal solutions for biomedical applications

Founders: Julien Alberici & Frederic Chaput

Registered Office: 22 rue des Aulnes, 69410 Champagne au Mont d'Or, France

Board Member representing IF in Mathym:

Stéphane Roussel

Mathym was created in 2013, based on a technology under exclusive licence of CNRS and Université de Lyon 1.

Mathym is a nanotechnology company dedicated to the development, manufacturing and commercialization of nanomaterials in the form of colloidal solutions. Mathym specialises in biomedical applications by developing innovative nanomaterials entering new medical devices formulation, such as dental or bone-substitute materials.

DEAL BACKGROUND & INVESTMENT RATIONALE

Innovation Fund decided to invest in Mathym for its know-how in materials science and its development potential. The investment financed the construction of the first production facility.



Julien Alberici
CEO

"I deeply and jointly believe in innovation and industry. So does the Innovation Fund. Thanks to this second financing round, Mathym has been able to build its first manufacturing line and to pursue its innovation and R&D developments."

investment of Innovation Fund	500.000 €
FTE's end of 2016	9
increase in FTE's 2016/2015	+2
sales 2016	0

TRANSACTION SUMMARY

On October 5th, the Innovation Fund invested EUR 500.000 in Mathym. Other investors are Kreaxi, Ravenala, Octalfa and Mr Lermusiaux. The financing round amounted to EUR 2.2m.

CAPITAL STRUCTURE ON 31/12/2016

shareholder	%
founders	23,34
Kreaxi	18,00
Pertinence Invest	6,91
Octalfa	28,59
Ravenala Holding	5,85
P. Lermusiaux	0,70
INNOVATION FUND	11,70
ESOP	4,91
total	100

KEY EVENTS AND ACTIONS IN 2016

Mathym entered into two new collaborations with top leaders in the dental field. Benefits brought by the colloidal solutions are highly valued within this highly competitive market.


Mathym built its first manufacturing line with a capacity of 2 tons of ytterbium fluoride (YbF3) nanoparticles dispersed in various media. YbF3 is the favourite radiopacifier used in dental composites formulations.

Mathym implemented ISO 9001:2015 QMS and was certified by Tüv Rheinland in December.

EXPECTATIONS 2017

Commercialization of the first YbF3 colloidal batch is expected in late Q2. The company will close an important partnership on ceramic development in the dental market. Mathym will participate to IDS in Köln and will move to new premises.

SALES FORECAST in 000 EUR



Aerosint



COMPANY DESCRIPTION

Sector: Materials

Activity: Innovative zero waste powder bed 3D printing process

Founders: M4KE IT, Edouard Moens de Hase & Matthias Hick

Registered Office: Rue des Pôles, 1, 4000 Liège

Board Member representing IF in Aerosint: Thierry Piret

Aerosint is a spin out of M4ke.it, created in 2016.

Selective laser sintering (SLS) is a 3D printing technology that wastes a significant percentage of its raw materials, hence relatively expensive and economically unsuitable for a wide range of applications.

Aerosint has designed a laser sintering technique that wastes no powder. This makes the technology both much cheaper and particularly well suited for the printing of high performance polymers like PEEK and PEKK. Aerosint developed a unique powder deposition mechanism, for which a patent is pending.


DEAL BACKGROUND & INVESTMENT RATIONALE

IF believes that reducing waste of expensive polymers will open new markets to 3D printing.



Edouard Moens de Hase
CEO

"The innovation fund brings us valuable materials expertise, crucial to be successful in the 3D printing hardware market. This expertise combined to a wide and international network helps Aerosint towards a quick go to market!"



FTE's end of 2016	3
sales 2016	0

TRANSACTION SUMMARY

Innovation Fund and Meusinvest both invested EUR 147.000 in Aerosint with the right to increase their investment during the next year.

CAPITAL STRUCTURE ON 20/02/2017

shareholder	%
M. Matthias HICK	18,31
M. Charles-Edouard MOENS de HASE	14,08
M4KE.IT S.P.R.L.	38,03
SPINVENTURE S.A.	14,79
INNOVATION FUND	14,79
total	100

KEY EVENTS AND ACTIONS IN 2016

In 2016, the Aerosint team validated the technical feasibility, the business case and the commercial opportunity. The results led to the incorporation of the company, the filing of patent applications and a first round of fundraising.

EXPECTATIONS 2017

Aerosint will boost its electronics capabilities by hiring a new engineer. The company aims to have a fully functional industrial laser sintering system by September.

SALES FORECAST in 000 EUR





THE INNOVATION FUND